Navigation Links
Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
Date:3/3/2008

GAITHERSBURG, Md., March 3 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that it will release fourth quarter and year-end 2007 financial results before the markets open and hold a conference call and live webcast to discuss corporate and clinical progress on Thursday, March 6, 2008 at 1:30 p.m. Eastern Time.

Conference Call Details

To access the live conference call on Thursday, March 6 at 1:30 p.m. Eastern Time via phone, please dial 866-578-5784 from the United States and Canada or +1-617-213-8056 internationally. The conference ID is 87233725. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through March 10 and may be accessed by dialing 888-286-8010 from the United States and Canada or +1-617-801-6888 internationally. The replay passcode is 74369365.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company's website at http://www.iomai.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

About Iomai Corporation

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
2. Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13
3. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
4. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
5. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
6. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
7. MiMedx Announces Brian J. Splan as President
8. Boston Scientific Announces European Approval of New Heart Failure Lead
9. WaferGen Announces Management Team Promotions
10. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
11. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, the industry’s pioneer in ... life sciences industry, today announces a strategic partnership with Alcami Corporation, a leading ... of Beaker’s expertise in executive recruitment solutions, providing Alcami with access to the ...
(Date:6/22/2017)... ... June 21, 2017 , ... Building on the success of ... more informative on the very latest developments in radical life extension. RAADfest combines cutting ... festival, and the empowerment of personal development, making it the largest most comprehensive and ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... in designating infertility as a disease, bringing new hope for prospective parents who ... 2017 annual meeting to back the World Health Organization’s designation in hopes of ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell Consulting’s ... biopharma and life sciences industries, continue to be in demand for their insights ... will be speaking on “The State of Information Governance in the Biopharmaceutical Industry” ...
Breaking Biology Technology:
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
Breaking Biology News(10 mins):